HBV Treatment
Which Pegylated Interferon alfa-2b Regimen Works Best for Chronic Hepatitis B?
- Details
- Category: HBV Treatment
- Published on Friday, 05 November 2010 12:48
- Written by Liz Highleyman
People with hepatitis B "e" antigen (HBeAg) positive chronic hepatitis B virus (HBV) infection respond best to a regimen of pegylated interferon alfa-2b (PegIntron) administered at 1.5 mcg/kg/week for 48 weeks, compared with a lower dose and/or shorter duration, according to a Chinese study presented last week at the American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston.
Tenofovir (Viread) Maintains HBV Suppression without Resistance for 4 Years
- Details
- Category: HBV Treatment
- Published on Monday, 01 November 2010 12:48
- Written by Press Release
The nucleotide analog tenofovir (Viread) continued to demonstrate potent activity against hepatitis B virus (HBV) through 4 years, researchers reported at the American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston. In preliminary analyses from Study 102 (HBeAg negative patients) and Study 103 (HBeAg positive patients), HBV viral load remained suppressed, tenofovir was well-tolerated with only a few cases of elevated creatinine (a marker of impaired kidney function), and no drug-resistance mutations were detected. Subgroup analyses from the same studies showed that tenofovir worked well for Asian participants and people with high baseline HBV viral load.
Add-on adefovir (Hepsera) Is More Effective and Durable Than a Switch to entecavir (Baraclude) as Rescue Therapy for Epivir-resistant Patients with Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 19 October 2010 02:10
- Written by HIVandHepatitis.com
Adding Hepsera is more effective and durable than switching to Baraclude as rescue therapy for Epivir-resistant patients with chronic hepatitis B, according to a study presented in Boston last week at AASLD 2010. The mean reduction of serum HBV DNA levels was significantly less in the Entecavir group than in the add-on Hepsera group at weeks 24 and 48. In addition, the rate of undetectable HBV DNA was significantly lower in the Entecavir group than in the add-on Hepsera group.
FDA Approves Entecavir (Baraclude) for Chronic Hepatitis B Patients with Decompensated Liver Disease
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 19 October 2010 12:49
- Written by Bristol-Myers Squibb
The U.S. Food and Drug Administration announced this week that it has approved the use of entecavir (Baraclude) to treat chronic hepatitis B virus (HBV) infection in people with decompensated liver disease, or liver failure. The expanded indication is supported by results from a Phase 3 trial showing that entecavir was more effective than adefovir (Hepsera) for this hard-to-treat patient population.
Pegylated Interferon Has Low Sustained Response Rate in HBeAg Negative Chronic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Friday, 17 September 2010 12:49
- Written by Liz Highleyman
Only about 1 in 5 patients with hepatitis B "e" antigen (HBeAg) negative chronic hepatitis B achieved sustained response to treatment with pegylated interferon, and about half that many reached undetectable HBV viral load, according to a study published in the August 2010 American Journal of Gastroenterology. Addition of ribavirin -- which helps prevent relapse in people with chronic hepatitis C -- did not significantly improve response rates.
More Articles...
- Long-term Entecavir Leads to Regression of Liver Fibrosis in Chronic Hepatitis B Patients
- Flares during HBV Treatment Do Not Predict Response, May Cause Liver Failure
- Adding Adefovir Works Better than Entecavir Monotherapy for Lamivudine-resistant Hepatitis B Patients
- How Long Do Chronic Hepatitis B Patients Need to be Treated to Sustain HBeAg Seroconversion?
Web Design and Development by